Abstract:Glioblastoma (GBM) is an unmet clinical need characterized by a standard of care (SOC) 5-year survival rate of only 5%, and a treatment mostly palliative. Significant hurdles in GBM therapies include an effective penetration of therapeutics through the brain protective barrier, namely the blood-brain barrier (BBB), and a successful therapeutic delivery to brain-invading tumor cells post-BBB crossing. These hurdles, along with the poor prognosis and critical heterogeneity of the disease, have shifted attention to treatment modalities with capacity to precisely and sequentially target (i) BBB cells, inducing blood-to-brain transport, and (ii) GBM cells, leading to a higher therapeutic accumulation at the tumor site. This sequential targeting allows therapeutic molecules to reach the brain parenchyma and compromise molecular processes that support tumor cell invasion. Besides improving formulation and pharmacokinetics constraints of drugs, nanomedicines offer the possibility of being surface functionalized with multiple possibilities of targeting ligands, while delivering the desired therapeutic cargos to the biological sites of interest. Targeting ligands exploit the site-specific expression or overexpression of specific molecules on BBB and GBM cells, triggering brain plus tumor transport. Since the efficacy of single-ligand functionalized nanomedicines is limited due to the GBM anatomical site (brain) and disease complexity, this review presents an overview of multi-ligand functionalized, BBB and GBM sequentially- and dual-targeted nanomedicines reported in literature over the last 10 years. The role of the BBB in GBM progression, treatment options, and the multiple possibilities of currently available targeting ligands will be summarized. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.

Blood-Brain Barrier Conquest in Glioblastoma Nanomedicine: Strategies, Clinical Advances, and Emerging Challenges

Advances in blood–brain barrier-crossing nanomedicine for anti-glioma

Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics

Targeted Regulation of Blood-Brain Barrier for Enhanced Therapeutic Efficiency of Hypoxia-Modifier Nanoparticles and Immune Checkpoint Blockade Antibodies for Glioblastoma

A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.

Contemporary strategies in glioblastoma therapy: Recent developments and innovations

Glioblastoma precision therapy: From the bench to the clinic.

The Blood-Brain/tumor Barriers: Challenges and Chances for Malignant Gliomas Targeted Drug Delivery.

Lipid-based nanoparticles to address the limitations of GBM therapy by overcoming the blood-brain barrier, targeting glioblastoma stem cells, and counteracting the immunosuppressive tumor microenvironment

How Nanotherapeutic Platforms Play a Key Role in Glioma? A Comprehensive Review of Literature

Emerging Blood-Brain-barrier-crossing Nanotechnology for Brain Cancer Theranostics.

Advances in Nanotechnology-Based Immunotherapy for Glioblastoma

The Nanocarrier Strategy for Crossing the Blood-Brain Barrier in Glioma Therapy

Potential of Nanocarrier-Associated Approaches for Better Therapeutic Intervention in the Management of Glioblastoma

Targeting brain tumors with innovative nanocarriers: bridging the gap through the blood-brain barrier

Nanomedicine facilitated cell signaling blockade: difficulties and strategies to overcome glioblastoma

Nanotherapeutic treatment of the invasive glioblastoma tumor microenvironment

Advances in nanotechnology for the treatment of GBM

Brain-targeted Nano-architectures for Efficient Drug Delivery and Sensitization in Glioblastoma

Targeting the undruggable in glioblastoma using nano-based intracellular drug delivery

Multi-ligand functionalized blood-to-tumor sequential targeting strategies in the field of glioblastoma nanomedicine.